With the standard April 5th National Institutes of Health (NIH) SBIR/STTR deadline officially in the rearview mirror, many early stage tech startups across the country, including university and academic medical center (AMC) startup teams, are breathing a collective sigh of relief. The proposals are submitted, the late nights are over, and now it is time to wait.
For deep-tech and biomedical spin-offs, the work of crossing the well-known “Valley of Death”: the marathon time and financial gap between a promising laboratory discovery and an investable, commercially viable product development effort, is a long and demanding journey. As a part of bridging that gap, many high-potential founders look to non-dilutive federal funding under the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs as a part of their pre-seed and seed funding strategy. Known collectively as America’s Seed Fund, these programs deploy over $4 billion annually in non-dilutive capital, with an estimated $70–$80 billion deployed into emerging technology businesses since the program’s inception through FY2025.
The SBIR and STTR programs operate as the next phase in the federal technology R&D investment continuum, which provides the earliest form of risk capital for scientific discovery. For many decades, the federal government has funded ground-breaking scientific programs – rooted primarily in NIH R01 awards and NSF investigator-initiated grants at universities and academic medical centers – carrying no commercial mandate and, frequently, no visible commercial application at the time. Many of these programs produced no commercial outcome at all. But American industry stands tall on the shoulders of discoveries that did:
- Genentech. NIH-funded research into basic bacterial genetics at UCSF and Stanford produced the first recombinant DNA technology in 1973, with no therapeutic objective in view. The work led to the founding of Genentech – the first biotechnology company – which Roche acquired in 2009 for $47 billion, seeding an entire industry.
- Checkpoint Immunotherapy. James Allison spent the early 1990s conducting NIH-funded basic immunology research at UC Berkeley on immune checkpoint proteins, with no therapeutic agenda. His 1996 mouse studies launched a drug category now generating more than $30 billion annually in global sales (including Merck’s Keytruda and BMS’s Opdivo) and earned Allison the 2018 Nobel Prize in Physiology or Medicine.
- mRNA Vaccines. Katalin Karikó’s NIH-funded mRNA modification research at the University of Pennsylvania was repeatedly denied renewal; reviewers saw no application. Her 2005 collaboration with Drew Weissman ultimately underpinned both the BioNTech/Pfizer and Moderna COVID-19 vaccines (Moderna’s market capitalization exceeded $150 billion in 2021) and earned the 2023 Nobel Prize.
- CRISPR. NIH R01-funded research into bacterial adaptive immunity at UC Berkeley produced the 2012 CRISPR-Cas9 paper that launched a gene-editing industry. The work earned the 2020 Nobel Prize in Chemistry.
- Google. Larry Page and Sergey Brin developed PageRank under an NSF-funded digital library project at Stanford (Grant No. IRI-9411306). The algorithm gave rise to Alphabet, valued today at over $1.7 trillion.
The highly competitive SBIR program applies this same patient-capital logic at the company level, with commercial potential as an explicit evaluation criterion. Historic home runs include:
- Qualcomm received approximately $1.5 million in early SBIR awards from DoD and NSF to develop CDMA semiconductor technology. Co-founder Irwin Jacobs credited those awards for providing not just capital but a stamp of approval to private investors.
- iRobot accumulated more than $16 million in SBIR funding from the Army, Navy, and DARPA, using military robotics contracts to develop the autonomous navigation technology that became the Roomba consumer vacuum. It was inducted into the SBIR Hall of Fame in 2011.
- Symantec. The very first SBIR award ever issued – a $25,000 Phase I under NSF’s 1979 pilot program – went to Gary Hendrix to develop natural language computing. When the original recipient firm failed, Hendrix used the remaining funds to found Symantec, which became one of the world’s leading cybersecurity companies.
Across the program’s 43-year history, SBIR/STTR awardees have generated more than 70,000 patents, approximately 700 publicly traded companies, and are credited with 12 percent of all new drug approvals between 1996 and 2020.
Timely program update: after expiring on September 30, 2025 and operating under a continuing resolution, the SBIR and STTR programs were formally reauthorized through September 2031 in late March 2026 by broad bipartisan vote (345–41 in the House). The reauthorization – the Small Business Innovation and Economic Security Act – also introduces new “Strategic Breakthrough Awards” of up to $30 million for transformative technology priorities.³ This is good news for founders who can now plan multi-year SBIR strategies on stable ground.
Don’t Sleep on the STTR : Advantages and Current Award Limits
Unlike the SBIR program, an STTR mandates a formal partnership, requiring a non-profit research institution (such as a university or AMC) to perform at least 30% of the work, while the small business performs at least 40%. This structure allows faculty founders to leverage their institution’s cutting-edge wet labs and clinical infrastructure while simultaneously building independent enterprise value.
America’s Seed Fund is structured to systematically de-risk unproven technologies through a gated approach. For current funding cycles, participating agencies have established the following standard limits:
Phase I (Feasibility and Proof of Concept): Designed to establish the technical merit and commercial viability of a discovery, Phase I awards generally last 6 to 12 months. Current guidelines cap these initial awards at up to $314,363 for the NIH and $275,000 for the NSF.
Phase II (Prototype and Validation): Only successful Phase I awardees – or those qualifying for a Direct-to-Phase II – can compete for these larger grants, which fund scale-up operations, advanced prototyping, and early clinical validation over a two-year period. Current standard Phase II limits reach up to $2,095,748 for the NIH and $1,000,000 for the NSF. The NIH frequently grants SBA waivers exceeding these caps for highly capital-intensive projects, such as FDA clinical trials.
The Prime Directive: You Won’t Win Without IP
While a brilliant scientific abstract is necessary, federal reviewers evaluate these proposals as early-stage investors looking for a commercial return. For academic spin-offs, this means one thing: you will not win an SBIR or STTR award without a rock-solid Intellectual Property strategy.
A groundbreaking biomedical discovery is commercially worthless if a well-capitalized competitor can easily replicate it. If your spin-off does not have a clearly defined path to market – which requires an exclusive license, or at minimum a formalized option agreement, for the foundational patents from your university’s Technology Transfer Office – your proposal will be severely penalized or rejected. Reviewers demand proof of “Freedom to Operate.” IP is the moat that protects the government’s investment. If you do not legally own the right to monetize the technology, the government will not fund its development.
A Catalyst for Outside VC Capital
The financial mechanics of America’s Seed Fund are uniquely founder-friendly: the capital is entirely non-dilutive. The government takes no equity and does not claim ownership of IP developed under the award. It retains only a limited Government Use License – the right to use the technology for government purposes – which does not affect your commercial rights.
The true value of an SBIR/STTR award, however, extends far beyond the direct deposit. Federal agencies subject proposals to a grueling, peer-reviewed technical evaluation by the nation’s top scientific minds. Winning a Phase II award serves as elite, third-party validation that the underlying science is sound.
For life science and deep-tech venture capitalists who are inherently risk-averse regarding unproven university IP, this federal validation acts as a powerful de-risking signal. Landmark economic research by Sabrina Howell – analyzing DoE SBIR grants and widely cited as representative of the broader program’s leverage effect – found that winning an early-stage federal innovation award roughly doubles a startup’s probability of securing subsequent venture capital funding. By using federal dollars to fund the most technically risky stages of early R&D, founders preserve their equity, extend their runway, and negotiate substantially higher valuations when they do raise a priced Series A round.
An Opportunity to Leverage Federal Dollars Through State Economic Development: TBED and Matching Programs
As the funding landscape continues to evolve, the playbook for spinning out academic research is tightening. To secure these highly competitive federal dollars, founders must master a strategy encompassing strict grant limits, non-negotiable intellectual property requirements, and the leverage of state-level Technology-Based Economic Development (TBED) matching initiatives.
Despite the massive federal investment, there is a practical gap: SBIR/STTR funds are restricted to the R&D scope of the approved project. They generally cannot be used for general business operating expenses, entity formation costs, or commercial marketing activities.
To bridge the operational and funding gap faced by early-stage technology businesses and foster emerging industries, proactive states build robust TBED infrastructures. Twenty-eight states now offer dedicated federal grant matching programs, and the two most established and documented provide a useful benchmark for what Ohio advocates are now pursuing.
- Kentucky SBIR/STTR Matching Funds Award Program (KY Innovation, est. 2006) is the nation’s longest-running state matching program, providing competitive non-dilutive grants of up to $100,000 for Phase I awardees and $150,000 for Phase II awardees. Through February 2026, it had made 345 awards to 157 companies, leveraging $173 million in federal funding, creating 781 high-wage jobs, generating $129.6 million in sales and licensing revenue, and attracting 43 company relocations to the state – returning $7.50 in combined federal and private capital for every dollar of state matching funds.
- Massachusetts START Grant Program (MassVentures, est. 2012) takes a different approach, providing tiered commercialization grants of up to $800,000 per company to cover costs federal awards prohibit – market validation, IP strategy, business development, and prototype refinement. Since launch, MassVentures has deployed $41.7 million to 141 companies that have collectively raised more than $5.1 billion in follow-on private investment; the program received the SBA’s 2015 Tibbetts Award and its structure is precisely the template Ohio advocates are proposing to adopt.
- Ohio TBED Programs: Ohio is a compelling example of what is possible and what remains unfinished. Historically, the state’s Ohio Third Frontier program – which has deployed over $2.3 billion in technology investment since 2002 – has fueled the ecosystem through vehicles like the Technology Validation and Start-up Fund (TVSF), which has helped institutions and startups validate and license their technologies.¹¹ Ohio companies secured approximately 230 awards totaling over $156 million in federal SBIR/STTR funding in 2024.
Industry advocates are pushing for a new, formalized Ohio SBIR/STTR State Matching Program. Eddie Pauline, MBA, OhioCED – President and CEO of Ohio Life Sciences (OLS), the state’s leading life sciences trade association (formerly BioOhio, rebranded in 2022) – has been a leading voice for this initiative.¹³ As Pauline and OLS have highlighted in their ongoing advocacy before the Ohio General Assembly, localized state capital is the missing link needed to cover IP legal fees and keep the lights on between federal disbursements. The proposed program would provide critical, unrestricted gap funding by offering a 50% match of up to $50,000 for Phase I winners and up to $100,000 for Phase II winners – mirroring the Kentucky and Massachusetts models that have proven effective. As of this writing, no legislation has been formally introduced, but OLS continues to work with the Legislature to find a path forward.
One State’s Ecosystems in Action: Columbus and Cleveland Lead the Way
The impact of aligning world-class research institutions with SBIR/STTR funding and state TBED initiatives is vividly apparent in Ohio’s recent data. Moving into 2025 and 2026, Ohio’s pre-eminent research institutions continue to be the dominant drivers of the state’s technological spin-off activity.
Over the program’s full history, the Cleveland metropolitan area has generated 1,540 cumulative awards totaling more than $566 million to 247 unique companies – a track record that reflects the depth of an innovation ecosystem anchored by Case Western Reserve University, the Cleveland Clinic, University Hospitals, and NASA Glenn Research Center.
In greater Cleveland specifically, the academic research ecosystem is aggressively spinning out federally validated companies. According to SBIR.gov award data, Cleveland-area companies received 18 SBIR/STTR awards in 2024 totaling approximately $15.5 million: spanning NIH, DoD, NSF, and DOE programs across sectors including advanced medical imaging, cancer therapeutics, biomedical materials, digital health, and defense manufacturing. Eight of those 18 awards were Phase II (the stage requiring demonstrated proof of concept), representing more than $13.1 million and reflecting the depth and maturity of the region’s technology pipeline.
The following companies illustrate what that pipeline looks like in practice:
- Advanced Imaging Research, Inc. received a $2.55M NIH Phase II award for noninvasive MRI characterization, including compact neuroimaging systems for patients from neonate to adult. A CWRU-affiliated spinout operating since 1996 under the d/b/a SREE Medical Systems, the company has maintained a continuous SBIR track record across multiple award cycles – building a commercial medical imaging business without reliance on dilutive capital.
- CollaMedix, Inc. secured $1.99M in NIH Phase II funding to advance its collagen-based biotextile platform (including CollaSling for stress urinary incontinence) toward FDA 510(k) submission. Founded in 2018 on technology licensed from CWRU and University Hospitals, the company has raised more than $10 million primarily through federal grants, has received investment from the UH Haslam Sports Innovation Center, and recently expanded into a larger ISO Class 8 cleanroom manufacturing facility in Cleveland.
- Opsiclear LLC received a $1.93M NIH Phase II award for its 3D optical histopathology platform, which enables real-time intraoperative tumor visualization for head and neck cancer surgery. The company has reported raising more than $5 million in seed funding for early-stage development of its spatial AI imaging technology.
- BioInVision, Inc. was awarded a prestigious $2.5M NIH Phase II grant to commercialize CryoViz, an AI-driven cryo-imaging platform that generates whole-organism 3D images to identify healthy and diseased tissues ( including metastatic cancer cells) accelerating preclinical drug discovery. The company has raised more than $7.6 million entirely through 11 SBIR/STTR awards, achieving a 57 percent Phase I-to-Phase II conversion rate well above the national average, and serves more than 75 customers and institutions globally: a sustained, revenue-generating business built entirely without equity dilution.
- Biochip Labs, Inc. received a $904,947 NSF STTR Phase II grant (Award No. 2332121) to optimize the manufacturing and machine-learning automation of its “Endothelium-on-a-chip” microfluidic device, a drug-screening and companion diagnostics platform for sickle cell disease. The company operates a CLIA-certified lab providing blood-disorder testing services and has received support from the Ohio Development Services Agency in addition to multiple federal awards.
The Bottom Line
For university researchers, the transition from the lab bench to the commercial market is fraught with financial peril, particularly when heading to market under the banner of a startup company. The SBIR and STTR programs remain the gold standard for survival. With the April 5th deadline now passed, the clock is already ticking toward the standard September 5, 2026 receipt date, followed by January 5, 2027. The capital is waiting – but it will only go to founders who have locked down their IP, are leveraging their state’s TBED resources, and are prepared to use federal validation to build the next generation of great American companies.
For founders planning their next submission or building a multi-year SBIR strategy, the key upcoming dates are: NIH standard receipt dates of September 5, 2026 and January 5, 2027; NSF Phase I solicitations are accepted on a rolling basis through the open solicitation window posted at seedfund.nsf.gov.
Note – in addition to SBIR and STTR grants, early stage companies can compete for significant funding from ARPA-H and ARPA-E, both of which issue targeted Broad Agency Announcements and Funding Opportunity Announcements on irregular schedules. Both programs are worth monitoring closely for deep-tech biomedical and energy technologies that may not map neatly onto the NIH or NSF framework. The March 2026 reauthorization through September 2031 provides founders with a stable planning horizon they have not had since 2022, and the new Strategic Breakthrough Awards tier ($30 million maximum) is worth tracking for the most ambitious spinouts in your pipeline.
If you are a university researcher, faculty founder, academic medical center team, or institutional technology transfer professional navigating the transition from laboratory discovery to commercial enterprise, the attorneys at can help at each stage of that process. Our work in this space encompasses IP strategy and patent portfolio development, technology transfer and licensing negotiations, entity formation and equity structuring, investment readiness and venture capital transactions, and grant strategy including SBIR/STTR, ARPA-H, ARPA-E, and other federal and state funding mechanisms. We would welcome the opportunity to discuss where you are in the process.
To discuss your next steps, contact Ted Theofrastous, Partner and Chair, IP, Technology & New Ventures (TCT@kjk.com; 216.736.7290).